3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Sarcoma
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Liposarcoma
1
Histiocytoma, Malignant Fibrous
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Dermatofibrosarcoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
61
Cisplatin
37
Carboplatin
23
Radiotherapy
21
Cetuximab
19
Magnetic Resonance Spectroscopy
18
Paclitaxel
17
Specimen Handling
13
Docetaxel
12
Fluorouracil
11
Nivolumab
10
tislelizumab
9
Surgical Procedures, Operative
8
Radiotherapy, Intensity-Modulated
7
Radiation
7
cemiplimab
6
Standard of Care
6
Platinum
6
Chemoradiotherapy
6
Biopsy
6
1,2-diaminocyclohexaneplatinum II citrate
6
toripalimab
5
Drug Therapy
5
130-nm albumin-bound paclitaxel
5
atezolizumab
4
Taxes
4
Ipilimumab
4
Immunotherapy
4
Fluorodeoxyglucose F18
4
Cyclophosphamide
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Squamous Cell Carcinoma of Head and Neck
×
Histamine H2 Antagonists
×
Clear all
NCT06789172
2026-05-22
INVOKE
Epkin
Phase 1
Recruiting
166 enrolled